NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Granules now has a total of 58 ANDA approvals from US FDA
Pfizer is likely to show GSK significant competition
Apollo continues to invest in genomics technology and research for better patient care
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Subscribe To Our Newsletter & Stay Updated
